million
chronic
hepat
c
viru
hcv
carrier
throughout
world
estim
two
million
japan
hcv
major
caus
hepatocellular
carcinoma
hcc
japan
case
hcvrelat
addit
japan
number
patient
hcvrelat
hcc
increas
worldwid
hcv
associ
broad
spectrum
clinic
biolog
extrahepat
manifest
chronic
hcv
infect
link
lichen
planu
particularli
involv
oral
caviti
lichen
planu
common
among
hcvinfect
patient
japan
accord
studi
patient
infect
hcv
may
develop
lichen
panu
eros
type
oral
lichen
planu
olp
particular
caus
spontan
pain
eat
toothbrush
uncomfort
feel
mouth
sever
report
coexist
hcv
infect
syndrom
accord
research
hcvinfect
patient
salivari
flow
normal
valu
patient
syndrom
increas
risk
periodont
candidiasi
april
en
otsuka
pharmaceut
co
ltd
iwat
japan
releas
oral
care
gel
therapeut
dentifric
contain
hinokitiol
remov
stain
teeth
gener
oral
debri
effect
prevent
breath
odor
gum
diseas
periodont
infect
gingiv
inflamm
hinokitiol
natur
chemic
compound
found
wood
tree
famili
cupressacea
hinokitiol
signific
antimicrobi
efficaci
staphylococcu
aureu
propionibacterium
acn
coronaviru
trichophyton
candida
albican
report
show
lesion
symptom
olp
decreas
qualiti
life
olp
patient
hcvrelat
liver
diseas
visual
analogu
scale
va
simpl
frequent
use
method
evalu
variat
pain
intens
studi
investig
va
effect
patient
olp
associ
hcv
infect
studi
includ
nine
japanes
patient
male
femal
olp
posit
hcv
antibodi
antihcv
visit
clinic
kurum
univers
hospit
japan
novemb
novemb
patient
rang
age
year
averag
age
year
biopsi
specimen
subject
show
histolog
featur
characterist
olp
type
olp
includ
eros
patient
reticular
patient
treat
topic
administr
steroid
elimin
irrit
factor
exampl
bad
fill
illfit
dentur
sera
nine
patient
evalu
white
blood
cell
count
wbc
red
blood
cell
count
rbc
hemoglobin
hb
platelet
plt
follow
liver
function
test
carri
aspart
aminotransferas
ast
alanin
aminotransferas
alt
gammaglutamyl
transpeptidas
alkalin
phosphatas
alp
lactat
dehydrogenas
ldh
albumin
alb
total
bilirubin
tbil
creatinin
blood
level
hemoglobin
fast
blood
glucos
fb
measur
ultrasonograph
examin
perform
patient
order
investig
shape
liver
lesion
occupi
liver
comput
tomographi
liver
biopsi
perform
patient
oral
care
gel
therapeut
dentifric
includ
hinokitiol
appli
patient
thin
layer
oral
membran
meal
bedtim
day
inform
consent
accord
helsinki
declar
ii
particip
studi
obtain
patient
use
simpl
lowcost
test
detect
xerostomia
requir
chew
piec
gauz
min
salivari
flow
rate
min
judg
decreas
salivari
secret
va
horizont
line
millimet
length
anchor
word
descriptor
end
illustr
figur
patient
mark
line
point
felt
repres
percept
current
state
dri
mouth
breath
odor
oral
fresh
oral
pain
rest
oral
pain
mealtim
tast
disord
loss
appetit
sleep
disord
depress
mood
jitteri
va
score
determin
measur
millimet
left
hand
end
line
point
patient
mark
data
express
mean
standard
error
statist
comparison
applic
day
made
use
wilcoxon
test
statist
analys
carri
use
jmp
version
sa
institut
cari
nc
usa
level
statist
signific
defin
characterist
nine
patient
studi
shown
tabl
diagnosi
liver
diseas
includ
chronic
hepat
c
n
liver
cirrhosi
posttreat
hcc
n
post
interferon
ifn
treatment
chronic
hepat
c
n
concomit
medic
complic
includ
hypertens
n
diabet
mellitu
dm
n
asthma
n
distribut
va
score
applic
shown
tabl
va
score
lower
applic
use
therefor
applic
improv
qualiti
life
accord
criteria
subject
evalu
dri
mouth
breath
odor
oral
fresh
sleep
disord
significantli
improv
day
applic
p
p
p
p
tabl
subject
evalu
oral
pain
mealtim
tast
disord
improv
day
applic
p
tabl
analyz
chang
laboratori
data
applic
tabl
chang
olp
character
chronic
inflamm
often
associ
sever
pain
burn
sensat
mouth
particular
chronic
eros
olp
pain
diseas
induc
sever
disabl
weight
loss
poor
qualiti
life
report
qualiti
life
spanish
patient
olp
reduc
patientcent
measur
consid
manag
olp
oral
candida
albican
also
may
isol
patient
olp
candida
albican
isol
special
virul
attribut
might
cofactor
contribut
develop
olp
especi
eros
olp
oral
care
gel
efficaci
candida
albican
improv
qualiti
life
olp
patient
therefor
use
agent
improv
subject
complaint
previous
report
sensit
tast
zinc
level
decreas
patient
hcvassoci
liver
diseas
patient
decreas
sensit
tast
despit
fact
unawar
tast
disord
addit
poor
oral
health
report
hcvinfect
patient
previou
studi
dental
problem
delay
initi
ifn
therapi
maximum
day
hcvinfect
patient
treat
ifn
therapi
manag
intens
oral
care
lower
resist
infect
therapi
regard
pain
olp
conceiv
oral
caviti
hcv
infect
like
becom
less
healthi
one
without
hcv
infect
necessari
hepatologist
educ
patient
regard
oral
hygien
well
provid
treatment
liver
diseas
qualiti
life
patient
hcvrelat
liver
diseas
decreas
import
appar
effect
care
use
lack
side
effect
conclus
show
oral
care
gel
improv
subject
symptom
patient
olp
result
studi
indic
use
could
effect
reduc
subject
symptom
qualiti
life
patient
olp
olp
oral
lichen
planu
hcv
hepat
c
viru
chc
chronic
hepat
c
lcc
liver
cirrhosi
type
c
hcc
hepatocellular
carcinoma
dm
diabet
mellitu
ifn
interferon
svr
sustain
virolog
respons
author
declar
compet
interest
yn
carri
data
collect
draft
manuscript
ms
contribut
data
analysi
author
read
approv
final
manuscript
sourc
support
studi
support
part
grantinaid
scientif
research
c
ministri
educ
cultur
sport
scienc
technolog
japan
